Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

Total article views   HTML views PDF downloads Totals
9,630 Dovepress* 8,714+ 1,150 9,864
PubMed Central* 916 233 1,149
Totals 9,630 1,383 11,013
*Since 8 November 2019
Total mentioned Facebook Delicious Reddit Twitter Others
7 0 0 0 2 5

View citations on PubMed Central and Google Scholar